AstraZeneca Prilosec OTC Prevention Claim Up For Committee Review Oct. 20
Executive Summary
AstraZeneca is seeking a prevention claim for an over-the-counter version of its proton pump inhibitor Prilosec (omeprazole).
You may also be interested in...
AstraZeneca Ramps Up U.S. Sales Force Before Nexium, Statin Launches
AstraZeneca plans to hire more in-house sales reps and decrease its "substantial reliance on contract sales organizations," Senior VP-Commercialization and Portfolio Management David Brennan said at the company's half-year results presentation in London Aug. 1.
AstraZeneca Uses Over 1,800 Outsource Sales Reps; Plendil Handled By PCA
AstraZeneca is outsourcing almost one-quarter of its promotional spending, including all promotional activities for its calcium channel blocker Plendil.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011